Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1997 1
1998 1
2000 1
2001 4
2002 5
2003 1
2004 2
2005 2
2006 6
2008 3
2009 1
2010 2
2011 3
2012 4
2013 13
2014 43
2015 75
2016 87
2017 75
2018 47
2019 26
2020 16
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 25865602

368 results
Results by year
Filters applied: . Clear all
Page 1
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
Vitale A, Spolverato G, Burra P, De Feo TM, Belli L, Donato F, Baroni GS, Marianelli T, Picciotto A, Toniutto P, Bhoori S, Passigato N, Lucà MG, Russo FP, Cillo U, Fagiuoli S; Liver Transplantation NITp working group. Vitale A, et al. Transpl Int. 2015 Sep;28(9):1055-65. doi: 10.1111/tri.12591. Epub 2015 Apr 30. Transpl Int. 2015. PMID: 25865602 Free article.
Management of hepatitis C infection before and after liver transplantation.
Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L. Fagiuoli S, et al. World J Gastroenterol. 2015 Apr 21;21(15):4447-56. doi: 10.3748/wjg.v21.i15.4447. World J Gastroenterol. 2015. PMID: 25914454 Free PMC article. Review.
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR. Fontana RJ, et al. Liver Transpl. 2016 Apr;22(4):446-58. doi: 10.1002/lt.24416. Liver Transpl. 2016. PMID: 26890629 Free article.
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Donato MF, Morelli C, Romagnoli R, Invernizzi F, Mazzarelli C, Iemmolo RM, Montalbano M, Lenci I, Bhoori S, Pieri G, Berardi S, Caraceni P, Martini S; ITACOPS-SOF Bridging Study Group. Donato MF, et al. Liver Int. 2017 May;37(5):678-683. doi: 10.1111/liv.13322. Epub 2016 Dec 26. Liver Int. 2017. PMID: 27865034 Free article.
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Gardenier D, Ng M, Motamed D, Khaitova V, Bach N, Chang C, Grewal P, Bansal M, Agarwal R, Liu L, Im G, Leong J, Kim-Schluger L, Odin J, Ahmad J, Friedman S, Dieterich D, Schiano T, Perumalswami P, Branch A. Patel N, et al. World J Gastroenterol. 2016 Mar 7;22(9):2844-54. doi: 10.3748/wjg.v22.i9.2844. World J Gastroenterol. 2016. PMID: 26973423 Free PMC article. Clinical Trial.
Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
Ahmed A, Gonzalez SA, Cholankeril G, Perumpail RB, McGinnis J, Saab S, Beckerman R, Younossi ZM. Ahmed A, et al. Hepatology. 2017 Jul;66(1):46-56. doi: 10.1002/hep.29137. Epub 2017 May 27. Hepatology. 2017. PMID: 28257591
Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C. Stahmeyer JT, et al. PLoS One. 2017 Jan 3;12(1):e0169401. doi: 10.1371/journal.pone.0169401. eCollection 2017. PLoS One. 2017. PMID: 28046099 Free PMC article.
368 results
Jump to page